BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 29, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daklinza daclatasvir: Phase III data

Top-line data from an open-label, Asian Phase III trial in 159 patients with chronic HCV genotype 1b infection who were intolerant or ineligible for interferon (IFN) therapies showed that once-daily 60 mg oral Daklinza daclatasvir plus twice-daily 100 mg oral Sunvepra asunaprevir for 24 weeks led to an...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >